Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of GBP 1.12 billion. The enterprise value is 599.12 million.

Market Cap	1.12B
Enterprise Value	599.12M

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+59.45%
Shares Change (QoQ)	-3.50%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	141.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.82
EV / Sales	0.84
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.24

Financial Position

The company has a current ratio of 0.93

Current Ratio	0.93
Quick Ratio	0.89
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.37
Interest Coverage	-17.46

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-10.76%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-54.57%
Revenue Per Employee	428,025
Profits Per Employee	-137,740
Employee Count	1,543
Asset Turnover	0.53
Inventory Turnover	19.68

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +194.65% in the last 52 weeks. The beta is 2.09, so Novavax's price volatility has been higher than the market average.

Beta (5Y)	2.09
52-Week Price Change	+194.65%
50-Day Moving Average	8.79
200-Day Moving Average	11.12
Relative Strength Index (RSI)	45.23
Average Volume (20 Days)	89,547

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.15

Income Statement

In the last 12 months, Novavax had revenue of GBP 660.44 million and -212.53 million in losses. Loss per share was -1.49.

Revenue	660.44M
Gross Profit	86.15M
Operating Income	-216.38M
Pretax Income	-208.71M
Net Income	-212.53M
EBITDA	-181.49M
EBIT	-216.38M
Loss Per Share	-1.49

Full Income Statement

Balance Sheet

The company has 678.60 million in cash and 195.65 million in debt, giving a net cash position of 482.96 million.

Cash & Cash Equivalents	678.60M
Total Debt	195.65M
Net Cash	482.96M
Net Cash Per Share	n/a
Equity (Book Value)	-392.77M
Book Value Per Share	-2.45
Working Capital	-57.69M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -67.81 million and capital expenditures -14.90 million, giving a free cash flow of -82.70 million.

Operating Cash Flow	-67.81M
Capital Expenditures	-14.90M
Free Cash Flow	-82.70M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 13.04%, with operating and profit margins of -32.76% and -32.18%.

Gross Margin	13.04%
Operating Margin	-32.76%
Pretax Margin	-31.60%
Profit Margin	-32.18%
EBITDA Margin	-27.48%
EBIT Margin	-32.76%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-59.45%
Shareholder Yield	-59.45%
Earnings Yield	-18.98%
FCF Yield	-7.38%

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Novavax has an Altman Z-Score of -3.81. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.81
Piotroski F-Score	n/a